Duke University: Gliosarcoma trials

The registry lists 17 Gliosarcoma studies with Duke University as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 4Phase 2 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Bevacizumab Beyond Progression (BBP)CompletedNCT01740258Phase 2Results posted
• Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)TerminatedNCT01186406Phase 2Results posted
• Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for GlioblastomaCompletedNCT01004874Phase 2Results posted
• A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)TerminatedNCT00735436Phase 2Results posted
• Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma MultiformeCompletedNCT00672243Phase 2Results posted
• Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)CompletedNCT00671970Phase 2Results posted
• Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)CompletedNCT00615927Phase 2Results posted
• Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + IrinotecanCompletedNCT00613028Phase 2Results posted
• Ph II Bevacizumab + Etoposide for Pts w Recurrent MGCompletedNCT00612430Phase 2Results posted
• Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and GliosarcomasCompletedNCT00612339Phase 2Results posted
• Phase II Avastin + Bortezomib for Patients With Recurrent Malignant GliomaCompletedNCT00611325Phase 2Results posted
• Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and GliosarcomasCompletedNCT00597402Phase 2Results posted
• Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive MeningiomaCompletedNCT00354913Phase 2Results posted
• Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBMCompletedNCT00612989Phase 1
• PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant GliomasCompletedNCT00612651Phase 1
• Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic GliomasCompletedNCT00612638Phase 1
• Ph I Dasatinib + Erlotinib in Recurrent MGCompletedNCT00609999Phase 1